Induction of transcription from the human immunodeficiency virus 1 long terminal repeat by the RelA (p65) NF-B subunit has been shown to be dependent upon an interaction with the zinc finger DNA-binding domain of Sp1. It was unknown, however, whether NF-B could also interact with other zinc finger-containing transcription factors. In this study we demonstrate that the early growth response transcription factor Egr-1, whose DNA-binding domain shares a high degree of homology with that of Sp1, can also interact with RelA in vitro and regulate NF-B transcriptional activity in vivo. Similar to the interaction with Sp1, the Rel homology domain of RelA interacts with the zinc finger domain of Egr-1. Surprisingly, and in contrast to Sp1, Egr-1 specifically represses RelA transcriptional activity through its zinc finger domain. Moreover, the interaction between RelA and the Egr-1 zinc fingers is mutually exclusive with DNA binding suggesting a model in which Egr-1 directly sequesters NF-B from its target promoters. Because Egr-1 is induced by many of the same stimuli that activate NF-B, this novel transcriptional regulatory mechanism has many implications for the involvement of both factors in cellular processes such as apoptosis and the response to stress and infection.
In response to changes in its local environment, including for example insult by DNA-damaging agents and hypoxia or exposure to growth factors and cytokines, the cell initiates a highly coordinated cascade of intracellular signaling pathways that ultimately modulate the pattern of gene expression. Both NF-B 1 and Egr-1 (also known as NGFI-A, Krox-24, or Zif268) are examples of transcription factors that function as important regulators of such cellular responses.
NF-B is a heterodimeric or homodimeric complex formed from five distinct subunits, RelA (p65), RelB, c-Rel, NF-B1 (p105/p50), and NF-B2 (p100/p52) (1) (2) (3) . These subunits share a sequence of approximately 300 amino acids within their amino termini, termed the Rel homology domain (RHD), which mediates DNA binding, dimerization, and interactions with heterologous transcription factors. NF-B1 and NF-B2 share a high degree of homology and are both synthesized as precursor proteins. Both remain in the cytoplasm until proteolytic processing yields the DNA-binding isoforms termed p50 and p52, respectively. In contrast, RelA, RelB, and c-Rel do not require proteolytic processing and contain transactivation domains within their carboxyl termini. Distinct combinations of subunits determine the specificity of transcriptional activation (3) , and although most NF-B subunits freely homo-and heterodimerize, there are some exceptions with RelB only efficiently dimerizing with p50 and p52 (4) .
NF-B expression is rapidly induced by a range of stimuli including ionizing radiation, cytokines such as tumor necrosis factor ␣ (TNF␣) and interleukin 1, growth factors, bacterial lipopolysaccharide, phorbol esters, and hypoxia (1, 2, 5) . In the majority of unstimulated cell types, NF-B is retained within the cytoplasm in an inactive form bound to its inhibitor protein IB (1, 2, 5) . With most inducers of NF-B, IB is rapidly phosphorylated and thus becomes targeted for ubiquitination and subsequent degradation by the proteosome. This releases NF-B, allowing it to translocate to the nucleus where it can induce the expression of a diverse array of gene products, such as cytokines, growth factors, adhesion molecules, immunoreceptors, and other transcription factors that mediate the cellular response to the initial stimulus (1, 2, 5, 6) . These genes will vary, however, dependent on the cell type and the nature of the stimulation. NF-B is also an important regulator of cellular apoptosis. The RelA knockout mouse dies in utero as a result of extensive liver apoptosis (7) . Furthermore, activation of RelA has been shown to promote resistance to apoptosis induced by TNF␣, ionizing radiation, and cancer therapeutic compounds (8 -11) . Under some circumstances, however, activation of NF-B can lead to the induction of apoptosis (12, 13) .
A number of mechanisms exist to regulate the specificity of transcriptional activation by NF-B. Different NF-B homoand heterodimers have subtly different DNA-binding specificities which can result in differential targeting to variant B elements within promoters and enhancers (3). Moreover, activation of different NF-B subunit combinations will vary depending on the cell type, the stimulus, and the time point after activation (3) . In addition to these important regulatory mechanisms, however, the interaction of different subunit complexes with heterologous transcription factors can also determine the selectivity and specificity of NF-B-mediated gene activation. For example, RelA has been shown to interact with the serum response factor and with many b-Zip containing proteins, such as members of the C/EBP and Fos/Jun families of transcription factors (3). RelA has also been shown to both bind DNA cooperatively and physically associate with the zinc finger containing transcription factor Sp1 (14, 15) . Efficient induction of transcription from the human immunodeficiency virus 1 (HIV-1) long terminal repeat by RelA was shown to require this interaction with Sp1, which was mediated by the RHD and zinc finger domains of these proteins respectively (14, 15) . It was unknown, however, whether NF-B transcriptional activity was regulated by interactions with other similar zinc fingercontaining transcription factors.
Egr-1 is an 80-kDa phosphoprotein and a member of the early growth response family of transcription factors which also includes Egr-2, Egr-3, and Egr-4 (16, 17) . These proteins contain a DNA-binding domain, homologous to that found in Sp1, composed of three zinc fingers of the C2H2 type that recognizes the consensus, GC-rich, DNA sequence 5Ј-GCG(G/ T)GGGCG-3Ј (18, 19) . Interestingly, the zinc finger domain of Egr-1 alone has been shown to be capable of inhibiting tumor cell growth (20) . In many promoters, Sp1 and Egr-1 binding sites have been shown to overlap with induction of Egr-1 preventing Sp1 from interacting with its recognition element (21) (22) (23) (24) (25) (26) (27) .
A number of recent reports suggested that Egr-1 might function similarly to Sp1 and both interact with and modulate NF-B transcriptional activity. The expression of Egr-1 can be induced by a range of stimuli, which in many cases overlap with those known to be capable of inducing NF-B expression. These include ionizing radiation (28, 29) , growth factors (30 -32) , hypoxia (33) , tissue damage (34) , and phorbol esters (22, 35, 36) . Similar to NF-B, Egr-1 regulates many genes involved in the immune and stress response pathways such as interleukin 2 (27, 37) , the IL-2 receptor ␤ chain (38) , CD44 expression in B-cells (39, 40) , intracellular adhesion molecule 1 (36), multidrug resistance gene 1 (22) , basic fibroblast growth factor (31) , and tissue factor (32, 33) . A number of studies have shown that, similar to NF-B, Egr-1 can both induce or suppress apoptosis (28, (41) (42) (43) (44) (45) (46) . Interestingly, Egr-1 can also induce expression of TNF␣, a potent activator of NF-B (28, 47) . Furthermore, NF-B and Egr-1 cooperate to induce expression of the NF-B1 gene, although in this report the authors indicated that they did not observe any direct interaction between the proteins (48) .
Given these observations and our interest in whether other zinc finger-containing transcription factors might modulate NF-B function, we have investigated whether Egr-1 can interact with and regulate RelA transcriptional activity. We have found that Egr-1 specifically represses NF-B transcriptional activity. Surprisingly, this repression occurs through its zinc finger DNA-binding domain. Moreover, the RHD of the RelA NF-B subunit specifically interacts with the Egr-1 zinc fingers but in a manner mutually exclusive with DNA binding, suggesting that Egr-1 might repress RelA by preventing its interaction with promoter target elements.
MATERIALS AND METHODS
Plasmids-The construction and sequence of the 2X B and B/Sp1 E1B CAT reporter plasmids have been described previously (14, 15) . All RelA-containing expression plasmids, except pcDNA3 Gal4 RelA, have been previously described (14, 15, 49) . pcDNA3 Gal4 was constructed by subcloning Gal4 from plasmid pBXG1 (supplied by Dr. Tom Glaser) into the HindIII and XbaI sites of pcDNA3. The activation domain of RelA (from amino acids 428 -551) was then amplified by polymerase chain reaction (PCR) using Pfu Turbo (Stratagene) and inserted into the BamHI and XbaI sites of pcDNA3 Gal4. The RSV-IB␣ transdominant negative expression construct has been detailed elsewhere (50) . The full-length human Egr-1 cDNA (pcDNA Egr-1) was the kind gift of Dr. Andrew Ward, University of Bath, United Kingdom. The pET3a Egr-1(ZnF) plasmid, containing the Egr-1 zinc finger domain (encoding aa 331-427) was constructed by PCR using Pfu Turbo with the following primers: 5Ј-CGCGGGATCCACACCCCCCCATGAACGCCCATATGCT-TGC-3Ј (sense), and 5Ј-CGCGGGATCCTCTAGATTAGTCTGCTTTCT-TGTCCTTCTGTCT-3Ј (antisense). The PCR product was isolated and subcloned into the BamHI site of pET3a downstream of the T7 tag, under the control of the T7 promoter. The pBS Egr-1 (NTD) plasmid, containing the amino-terminal domain of Egr-1 (encoding aa 1-330), was amplified using the following primers: 5Ј-CGCGTCGACAAGCT-TCACCATGGCCGCGGCCAAGGCCGAGATGC-3Ј (sense), 5Ј-CGCTC-TAGATTACTTGCTGGGCCGGTTGGG-3Ј (antisense). The PCR product was isolated and subcloned into the SalI-XbaI sites of Bluescript under the control of the T7 promoter. To optimize expression of fulllength Egr-1 in human 293 cells, the full-length cDNA was amplified using PCR with the Egr-1 amino-terminal sense primer (see above) in conjunction with a carboxyl-terminal primer 5Ј-CGCTCTAGATTAG-CAAATTTCAATTGTCCTGGG-3Ј (antisense) and then subcloned as a SalI-XbaI fragment into the pVR 1012 cytomegalovirus expression plasmid (51) (used with the permission of Vical Inc.). The pcDNA3 Egr-1 (ZnF) plasmid was created by PCR from pET3a Egr-1 (ZnF) using the following primer: 5Ј-GCGCAAGCTTCACCATGGCTAGCATGACT-GGTGG -3Ј (sense), which encodes the T7 tag from pET3a and the Egr-1 ZnF-antisense primer (see above). The desired PCR product was isolated and subcloned as a HindIII-BamHI fragment into pcDNA3. Plasmids pBS-Sp1FL (encoding full-length Sp1), pET-Sp1 (N-terminal) (encoding aa 81 to 613), and pET-Sp1 (ZnF) (encoding the Sp1 zinc fingers) have all been described (14, 15) . The pcDNA3-Sp1 (ZnF) plasmid, which encodes the Sp1 zinc finger domain (encoding aa 560 -619) was amplified from pET-Sp1 (ZnF) using the same amino-terminal primer annealing to the pET3a T7 tag used to create pcDNA3 Egr-1 (ZnF) (see above) and 5Ј-GCAGGATCCTCTAGATTACTTCTTATTCTGGTGGG-TCTT-3Ј (antisense). The desired PCR product was isolated and subcloned as a HindIII-XbaI fragment into pcDNA3. All restriction sites in the oligonucleotides listed above are in bold italics with the Kozak sequences underlined and initiating methionine residues in bold.
Cell Culture and Stimulations-Techniques used for cell culture and TNF␣ stimulations have been described previously (52) .
Transient Transfections and Reporter Gene Assays-The calcium phosphate transient transfection of human U20S osteosarcoma cells and 293 embryonic kidney cells has been detailed previously (52) . All transfected cells were harvested at 24 h post-transfection except those used in electrophoretic mobility shift assay (EMSA) analysis and where endogenous, non-TNF␣-stimulated NF-B activity was being assayed, which were harvested after 48 h. Chloramphenicol acetyl transferase (CAT) activity was assayed on 20 -50 g of whole cell extract, except for those assays where endogenous NF-B activity was analyzed where 100 g was used. Data were scanned using a Fujifilm FLA-2000 phosphorimager and then quantitated using MacBas version 2.5 quantitation software (Fujifilm Photo company Ltd.).
EMSA and Protein Extracts-For the preparation of nuclear extracts, 293 cells were transfected with 10 -20 g of the appropriate plasmids. Transfected cells were then harvested 48 h later, and nuclear extracts were prepared as described (53) . EMSAs were performed using 5 g of crude nuclear extract in a 20-l reaction volume consisting of 20 mM HEPES (pH 7.9), 100 ng of poly(dI⅐dC) and ϳ0.1 ng of the appropriate [
32 P]dATP-labeled double-stranded oligonucleotide. Samples were incubated at room temperature for 15 min, and then DNA-protein complexes were resolved using 0.25ϫ Tris borate-EDTA-4% nondenaturing polyacrylamide gels.
GST "Pull Down" Assays-GST and GST RelA (RHD), expressed in Escherichia coli DH5␣, were purified using glutathione-agarose as described previously (15) . In vitro translated, [ 35 S]methionine-labeled proteins were synthesized using the TnT-Quick system (Promega Corp.) where the reticulocyte lysate had first been specifically depleted of endogenous NF-B using Sepharose-linked, multimerized doublestranded oligonucleotides containing an NF-B binding site.
GST or GST RelA (RHD) (ϳ1 g), bound to glutathione-agarose beads, was incubated with 5 l of in vitro translated, [ 35 S]methioninelabeled protein in 100 l of incubation buffer (20 mM HEPES (pH 7.9), 75 mM KCl, 2.5 mM MgCl 2 , 1 mM dithiothreitol, 0.1% (v/v) Nonidet P-40, 1 mM phenylmethylsulfonyl fluoride, 1 g/ml leupeptin, 1 g/ml aprotinin, and 1 mM NaV) for 1.5 h at 4°C. Where indicated, 100 ng of double-stranded oligonucleotides containing 1X B, 1X Egr-1, 2X B, 2X Egr-1, 1X E2F binding sites, a control DNA sequence derived from the angiotensinogen promoter, or the B and Egr-1 sites from the p105 promoter (with either the intervening spacer DNA present or deleted) (48) were added at this point. After incubation, the glutathione-agarose resin was washed with three 500-l volumes of incubation buffer before being resuspended in 20 l of SDS loading buffer and boiled for 10 min. Denatured proteins were then resolved by SDS-polyacrylamide gel electrophoresis. The gel was then fixed in a solution of 5% (v/v) glacial acetic acid, 5% (v/v) propan-2-ol, washed, submerged in Autofluor (National Diagnostics), dried, and then exposed to photographic film overnight at Ϫ80°C. The sequence of the B/Egr-1 oligonucleotide (sites are underlined) derived from the p105 promoter, sense strand only, is 5Ј-TCG-AGTAGGGCTTCCCCCACCCCCGGCAGCGACCCTACCTCCCGCCC-CCGCAGTG-3Ј. The sequence of the ⌬S B/Egr-1 oligonucleotide derived from the p105 promoter but with the spacer region deleted, sense strand only, is 5Ј-TCGAGTGCGGGCTTCCCCCACCCCGCC-CCCGCTGCGTG-3Ј.
RESULTS

Egr-1 Represses Transcriptional Activation by NF-B-
The zinc finger domain of Egr-1 is highly homologous with that of Sp1 and in many cases their respective DNA binding sites in cellular promoters have been found to overlap (21) (22) (23) (24) (25) (26) (27) . Because an interaction with the Sp1 zinc finger domain is required for NF-B-mediated stimulation of transcription from the HIV-1 long terminal repeat (14, 15) , we investigated whether Egr-1 could also regulate transactivation by the RelA NF-B subunit. Initial experiments were performed using a minimal B/Sp1 E1B CAT reporter plasmid, which contains the core 3Ј-NF-B and 5Ј-Sp1 motifs from the HIV-1 long terminal repeat. RelA activation of this reporter plasmid has been previously shown to require the Sp1 motif in mammalian cells (14) . Furthermore, RelA and Sp1 synergistically stimulate transcription from this promoter when cotransfected into Drosophila SL2 cells (15) . Interestingly, when an Egr-1 expression plasmid was cotransfected with RelA and B/Sp1 E1B CAT into U2OS cells, a strong repression of RelA-induced CAT activity was observed (Fig. 1A) . To determine whether this repression was occurring through Egr-1 binding directly to the Sp1 site or resulted from a direct effect on RelA itself, a minimal NF-B reporter plasmid was used containing two tandem B elements upstream of the adenovirus E1B TATA box (2X B E1B CAT) (15) . Surprisingly and similar to the result observed in Fig. 1A , Egr-1 repressed RelA-mediated transactivation of the 2X B E1B CAT plasmid, both as homodimer and when cotransfected with p50 (Fig. 1, B  and C) . In contrast, the DNA binding, -KTS form of the Wilms' tumor suppressor protein, another zinc finger protein with a DNA-binding domain homologous to Egr-1, did not repress RelA transactivation (Fig. 1B) . In addition, Egr-1 repressed both TNF␣-activated and constitutive NF-B transcriptional activity (Fig. 2, A and C) . A low level of constitutive NF-B activity is observed in many transformed cell lines (54) . In these experiments its identity was confirmed through co-expression of IB (Fig. 2B) , and its presence was revealed by leaving the transfected cells for a longer period prior to harvesting and using larger quantities of protein in the CAT assays. These latter experiments established that Egr-1 repression of NF-B does not result from an indirect effect on the RelA expression plasmid itself and can also occur under conditions when NF-B is naturally activated by TNF␣.
Further confirmation of the specificity of these observations was observed when Egr-1 was cotransfected with an expression plasmid encoding the Gal4 DNA-binding domain fused to the RelA transcriptional activation domain and the Gal4 E1B CAT reporter. Despite stimulating transcription to similar levels as RelA itself, no repression of Gal4 RelA was observed (Fig. 2D) . Similarly, no repression of a Gal4 VP16 expression plasmid by Egr-1 was observed (data not shown).
These observations suggested that Egr-1 repression of NF-B resulted from a direct effect on the RelA subunit itself rather than an indirect effect involving displacement of Sp1. Some NF-B binding sites have been reported to overlap with Sp1 binding sites (55) , suggesting that Egr-1 could be repressing RelA through directly binding the B elements and displacing it from the promoter. To ensure, therefore, that the Egr-1-mediated repression of RelA transactivation was not due to the presence of a cryptic Egr-1 binding site within the 2X B element, nuclear extracts from 293 cells transfected with both RelA and Egr-1 were prepared and used in an EMSA. In contrast to RelA-containing nuclear extracts, no evidence of Egr-1 binding to the 2X B oligonucleotide was observed (Fig. 3A) . Furthermore, an anti-Egr-1 antibody failed to shift any complexes binding this oligonucleotide. EMSA analysis performed with an Egr-1 binding site oligonucleotide confirmed the expression of Egr-1 and the integrity of the Egr-1 antibody (Fig. 3B) . 
the 2X B E1B CAT reporter plasmid and the RSV p50 (1 g), RSV RelA (1 g), or pcDNA Egr-1 (1 g) expression plasmids as indicated. In all experiments RSV ␤gal or pcDNA3 were included such that each transfection condition contained equivalent levels of expression plasmids. The results shown are the average of three separate experiments. The error bars represent calculated standard deviations.
Egr-1 Interacts with the Rel Homology Domain of RelA-To
ascertain whether Egr-1 could, like Sp1, interact with RelA, GST pull down assays were performed. In vitro translated full-length Egr-1 was seen to coprecipitate with GST-RelA not with GST alone (Fig. 4A) . Sp1 also bound GST-RelA at similar levels to Egr-1, whereas a luciferase negative control did not. Subsequent deletion analysis demonstrated that, analogous to Sp1, the zinc finger domain of Egr-1 was able to mediate the interaction between RelA and Egr-1 (Fig. 4B) . No interaction between the amino-terminal domain of Egr-1 and RelA was observed.
Previously it has been demonstrated that some specific interactions between transcription factors are DNA-dependent protein-protein interactions (56) and as such could be perturbed by the inclusion of the DNA-chelating agent ethidium bromide in the binding buffer. In many cases such interactions are probably the result of a catalytic effect, whereby DNAbinding proteins nonspecifically bind any contaminating DNA, resulting in an increased local concentration of the transcription factors, thus promoting their interaction. It is important to rule out, however, that any association does not result from fortuitous localization on the same DNA fragment, thus giving the appearance of an interaction. When increasing quantities of ethidium bromide were included with the GST RelA/Egr-1 interaction, a decrease in binding was observed (Fig. 4C) . At saturating quantities of ethidium bromide a strong interaction between RelA and Egr-1 remained, however, indicating that these transcription factors can associate in the absence of DNA.
The Egr-1 Zinc Finger Domain Represses Both Transfected RelA and Endogenous NF-B Transcriptional Activation-
Both RelA and Egr-1 have been shown to interact with the non-DNA-binding p300 and CREB-binding protein coactivator proteins (54, 57, 58) , both of which are present at limiting quantities in cells (59 -61) . With many transcription factors, transcriptional repression and cross-talk has been shown to result from competitive binding to p300 and CREB-binding protein (52, (61) (62) (63) . In addition, Egr-1 has been shown to contain a number of functional domains that complement its DNA-binding ability including both strong transcriptional activation and repression domains within its amino terminus (64 -66). Although Fig. 4B indicated that the interaction between RelA and Egr-1 is mediated by their respective DNAbinding domains, it could not be ruled out that other functions of Egr-1 might also contribute to the transcriptional repression observed in Figs. 1 and 2 . To investigate this question further, therefore, the zinc finger domain of Egr-1 alone was cotransfected with RelA into U2OS cells using the 2X B E1B CAT reporter plasmid. Significantly, the zinc finger domain of Egr-1 alone was able to strongly repress RelA (Fig. 5A ). In addition, the Egr-1 zinc fingers were able to repress endogenous NF-B activity, whereas, interestingly, the Sp1 zinc fingers did not (Fig. 5B) . These results suggested that competition for p300 or CREB-binding protein, or direct transcriptional inhibition through its repression domain are not required for Egr-1-mediated inhibition of NF-B transcriptional activity.
The Interaction between RelA and Egr-1 Is Mutually Exclusive with DNA Binding to Their Consensus Recognition Sequences-Taken together, these results suggested that the physical interaction between the Egr-1 zinc fingers and RelA is responsible for the transcriptional repression seen in vivo. One mechanism through which this might occur would be if direct binding of the Egr-1 zinc fingers prevented RelA interacting with the B elements in the promoter. EMSA analysis of nuclear extracts prepared from cells transfected with Egr-1 and either cotransfected with RelA or stimulated with TNF␣ did not reveal an inhibition of NF-B DNA-binding, however (data not shown). Indeed, consistent with previous observations (48) an induction of the p50 subunit could be observed in the form of increased levels of p50/RelA heterodimers (data not shown). Cotransfection of p50 demonstrated that this could not account for the repression effects seen. In fact an increase in NF-B activity could be observed (data not shown), probably resulting from the increased DNA-binding affinity of p50/RelA heterodimers relative to RelA homodimers (67) . The conditions under which these experiments are performed, however, did not rule out that inhibition of RelA DNA binding might underly the functional repression observed. First, the high salt used to prepare the nuclear extracts has been seen to disrupt the Egr-1/RelA interaction in vitro (data not shown). Second, in vitro, the affinity of a transcription factor for its DNA-recognition element could be expected to be much stronger than a protein-protein interaction with a heterologous transcription factor. In vivo, however, when DNA is assembled into chromatin, the affinity of most transcription factors for their recognition elements drops many orders of magnitude (68) making it more likely that a protein-protein interaction could disrupt this process.
Therefore, to investigate whether DNA binding and the Egr-1/RelA interaction might be mutually exclusive, the reverse experiment was performed. Double-stranded oligonucleotides containing either one or two copies of the B or Egr-1 consensus binding sites were included in a GST RelA pull down assay with in vitro translated Egr-1. Interestingly, these oligonucleotides strongly inhibited the interaction (Fig. 6A) . In contrast, double-stranded oligonucleotides containing either the E2F binding site or a control sequence had little effect on the RelAEgr-1 association. Similar effects were seen when these experiments were repeated with the zinc fingers of Egr-1 (Fig. 6B) . Significantly, the RelA-Sp1 zinc finger interaction was not inhibited to a similar extent when the 1X B oligonucleotide was included (Fig. 6, C and D) . These results indicate, therefore, that the interaction between RelA and Egr-1 is mutually exclusive with DNA binding to their consensus recognition sites. Moreover, it suggests that transcriptional repression by Egr-1 might result from direct inhibition of RelA DNA binding to the promoters used in this study. Furthermore, Sp1 neither represses nor acts in this manner, suggesting that this is an effect seen specifically with Egr-1. These observations were not consistent, however, with the previously observed transcriptional synergy between RelA and Egr-1 on the NF-B1(p105) promoter (48) . To address this question a double-stranded oligonucleotide was synthesized containing the third B and Egr-1 sites from this promoter that had previously been shown to function synergistically together. Interestingly, this oligonucleotide did not disrupt the interaction between RelA and Egr-1, whereas a similar oligonucleotide, in which the spacer region between the two sites had been deleted, did (Fig. 6E) . This observation indicates that where their sites are correctly juxtaposed, RelA and Egr-1 can both interact with the same promoter and thus cooperatively stimulate transcription.
DISCUSSION
In this report, we have demonstrated that the immediate early gene product, Egr-1, both functionally and physically interacts with the RelA subunit of NF-B. Similar to Sp1, this interaction is mediated by the zinc fingers of Egr-1, which bind the RHD of RelA. Unlike Sp1, however, this interaction is mutually exclusive with DNA binding and the Egr-1 zinc fingers specifically repress NF-B transcriptional activity. These observations suggest that Egr-1-mediated repression of RelA occurs through inhibition of its ability to bind B elements within target promoters in vivo. This regulatory mechanism thus distinguishes Egr-1 from other transcription factors, such as p53 and Stat2, that inhibit NF-B transactivation through sequestration of limiting quantities of the p300 and CREBbinding protein coactivator proteins (52, 61, 69, 70) .
Thus Egr-1 is part of a growing number of heterologous transcription factors that have been shown to interact with and modulate the transcriptional activity of NF-B. Most reported interactions result in cooperative stimulation of transcription. In many cases, such as with synergistic activation of the HIV-1 long terminal repeat by RelA and Sp1, this is dependent on the specific juxtaposition of their respective DNA binding sites (15) . In other examples, however, such as with serum response factor and c-Jun (71, 72) , cooperative stimulation of transcription required the binding site for just one of the transcription factors. In another example, C/EBP␤ cooperatively stimulates transcription from the IL-8 promoter with NF-B (73) . At other promoters containing just B elements, however, C/EBP␤ repressed NF-B transactivation (73) . Thus repression by Egr-1 is only one of many regulatory mechanisms that can determine the specificity of NF-B-induced gene expression. Upon activation, NF-B can potentially interact with a wide range of different proteins, which will compete with each other to target it to different promoters and enhancers. Once bound, the formation of stable enhanceosome-type structures (74) would prevent Egr-1 from interacting with RelA and inhibiting its ability to bind DNA. We suggest therefore, that at physiological levels, Egr-1 is unlikely to globally repress NF-B transcriptional activity. Rather, it will probably have a modulatory function with concomitant Egr-1 activation reducing but not abolishing the available pool of NF-B capable of forming these other interactions.
NF-B and Egr-1 have been shown to cooperatively stimulate transcription from the NF-B1 (p105) promoter (48), a result we have confirmed in EMSA analysis where we observe induction of p50 protein (data not shown). Consistent with this observation, we have observed that an oligonucleotide containing the B and Egr-1 sites from the NF-B1 (p105) promoter does not disrupt the interaction between RelA and Egr-1 (Fig.  6E) . Taken together, therefore, and similar to C/EBP␤, it is probable that Egr-1 will prove capable of functioning cooperatively with NF-B at some promoters, while sequestering and inhibiting its ability to activate others. Therefore, under conditions where induction of Egr-1 occurs at the same time as NF-B there would be a shift in the pattern of gene expression, relative to circumstances where Egr-1 is not present, with some genes being induced more strongly and others failing to be activated. An investigation of such events would probably require the use of genome wide expression analysis technology and will be the subject of future investigations.
In this report, we have not defined the physiological consequences of Egr-1-mediated modulation of NF-B. A recent report, however, demonstrated that ionizing radiation-induced apoptosis of PC-3 cells, a human prostate cancer line, was mediated by Egr-1 induction of TNF␣ (28) . TNF␣ also strongly activates NF-B (75), which then typically functions to promote resistance to programmed cell death (8 -10) . Inhibition of NF-B has been shown to sensitize cells to TNF␣-mediated apoptosis, and it has been demonstrated that this might have important therapeutic consequences for the treatment of cancer (11) . This observation in PC-3 cells suggested therefore that a mechanism involving Egr-1 must exist to prevent NF-Bmediated prevention of cell death. Our results would be consistent, therefore, with Egr-1 being able to block this function of NF-B. In some cell lines, with specific inducers, NF-B can actually induce apoptosis (12, 13) , suggesting that mechanisms must exist to switch its activity from genes that enhance resistance to apoptosis to those that induce cell death. It will therefore be the subject of future experiments to determine FIG. 6 . The interaction between Egr-1 and RelA is mutually exclusive with DNA-binding. A-C, the interaction of Egr-1 with GST-RelA (RHD) is inhibited by oligonucleotides containing NF-B or Egr-1 binding sites. [ 35 S]methionine-labeled, in vitro translated fulllength Egr-1 (A), Egr-1 zinc fingers (aa 331-427) (B), or Sp1 zinc fingers (aa 560 -619) (C) were incubated with GST RelA (RHD) or GST alone as indicated. Where shown, 100 ng of double-stranded oligonucleotides containing the indicated transcription factor binding sites were also included. After incubation and further washing, the complexes were resolved by SDS-polyacrylamide gel electrophoresis and subjected to autoradiography. A sample of input [
35 S]methionine-labeled material is shown. D, quantitation of the inhibition of the interaction between GST-RelA (RHD) and the Egr-1 or Sp1 zinc fingers. The results from three separate experiments were quantitated using a phosphorimager, and the level of binding upon addition of the 1X B oligonucleotide relative to the control oligonucleotide was calculated and averaged. The error bars represent calculated standard deviations. E, the interaction of Egr-1 with GST-RelA (RHD) is not inhibited by an oligonucleotide containing both NF-B and Egr-1 binding sites from the NF-B1 (p105) promoter. [ 35 S]methionine-labeled, in vitro translated full-length Egr-1 was incubated with GST RelA (RHD) or GST alone as indicated. Where shown, 100 ng of double-stranded oligonucleotides containing the indicated transcription factor binding sites were also included. After incubation and further washing, the complexes were resolved by SDSpolyacrylamide gel electrophoresis and subjected to autoradiography. A sample of input [
35 S]methionine-labeled material is shown.
whether Egr-1 might play a critical role in this switch, together with the other factors, such as cell type, that might underly this important cellular regulatory mechanism.
